Laboratorios Farmaceuticos Rovi reports Q2 results, reiterates outlook

Spanish pharmaceutical company Laboratorios Farmaceuticos Rovi reported H1 2025 results with a 4.5% sales decline to €314.6 million, primarily due to a 35.1% contraction in its CDMO business from lower mRNA contributions and a temporary facility closure that shifted revenue. Despite this, the company exceeded consensus estimates for EBITDA, which decreased 6.2% to €65.6 million, and improved its gross margin to 62.4%, driven by strong specialty pharma growth (+12.8%) and reduced LMWH raw material costs. Rovi reiterated its full-year 2025 mid-single-digit revenue decline guidance but raised its enoxaparin outlook, while maintaining its medium-term target to double CDMO sales by 2030.

Analysis

Laboratorios Farmaceuticos Rovi reported H1 2025 results that, while showing a top-line contraction, contain significant underlying strengths. The 4.5% year-over-year sales decline to €314.6 million was in line with consensus and driven entirely by a 35.1% drop in the Contract Development and Manufacturing Organization (CDMO) business. This weakness is attributed to lower mRNA-related contributions and a temporary facility closure that shifted revenue into Q4 2024, suggesting a timing issue rather than a fundamental deterioration. In contrast, the specialty pharmaceutical division demonstrated robust health, growing 12.8% to €237.4 million. A key positive was the 4% beat on EBITDA, which came in at €65.6 million versus a consensus of €63.1 million. Furthermore, gross margin expanded notably by 300 basis points to 62.4%, driven by a favorable mix from high-margin Okedi and a 33% decrease in LMWH raw material costs. While Rovi reiterated its full-year guidance for a mid-single-digit revenue decline, it upgraded its outlook for its enoxaparin product to a mid-single-digit increase, a material improvement from a previously guided decrease. The company's confidence is further underscored by its maintained medium-term target to double CDMO sales by 2030 and its on-track clinical pipeline, with key Phase III trials set to begin in Q4 2025.

Key Decisions for Investors

• Investors should look past the headline revenue decline, focusing instead on the robust growth in the specialty pharmaceutical business and the significant gross margin expansion to 62.4%, which signals strong operational health.
• The 4% EBITDA beat against consensus and the positive guidance revision for the enoxaparin franchise are bullish signals that may offset concerns about the temporary, timing-related weakness in the CDMO segment.
• Monitor the recovery of the CDMO business in the second half of the year and the initiation of key Phase III trials in Q4 2025, as these are critical catalysts for validating the company's long-term growth narrative.
• The reaffirmed medium-term target to double CDMO sales by 2030 presents a potential long-term value creation opportunity, but this must be weighed against the confirmed near-term pressure on full-year revenue.